Yung-Sheng Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yung-Sheng Li has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Chih-Hung Tsai
Graduate Institute of Integrated Medicine, China Medical University, Taichung 40402, Taiwan
1 shared publication - Le Huynh Hoai Thuong
Department of Pharmacology, School of Medicine, China Medical University, Taichung 404, Taiwan
1 shared publication - Trung-Loc Ho
Graduate Institute of Biomedical Sciences China Medical University Taichung Taiwan
1 shared publication - Yu-Huei Liu
Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan, ROC
1 shared publication - Yuan-Ho Lin
Graduate Institute of Integrated Medicine, China Medical University, Taichung 40402, Taiwan
1 shared publication
Latest Publications
- Open Access
- 26 August 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (17) , 9257
Integrated Medicine for Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of typical chemotherapeutics among cancer survivors. Despite the recent progress, the effective prevention and treatment strategies for CIPN remain limited. Better understanding of the pathogenesis of CIPN may provide new niches for developing a new ideal therapeutic strategy. This review summarizes the current understanding of CIPN and current recommendations along with completed/active clinical trials and aims to foster translational research to improve the development of effective strategies for managing CIPN.
- 26 August 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (17) , 9257
Open AccessIntegrated Medicine for Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of typical chemotherapeutics among cancer survivors. Despite the recent progress, the effective prevention and treatment strategies for CIPN remain limited. Better understanding of the pathogenesis of CIPN may provide new niches for developing a new ideal therapeutic strategy. This review summarizes the current understanding of CIPN and current recommendations along with completed/active clinical trials and aims to foster translational research to improve the development of effective strategies for managing CIPN.